Your browser doesn't support javascript.
loading
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu, Shun; Wu, Lin; Jian, Hong; Chen, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Sun, Meili; Han, Liang; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Li, Baolan; Pan, Yueyin; Li, Xingya; Ye, Feng; Liu, Anwen; Wang, Ke; Cang, Shundong; Zhou, Hui; Sun, Xing; Ferry, David; Lin, Yong; Wang, Shuyan; Zhang, Wen; Zhang, Chengli.
Afiliación
  • Lu S; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn.
  • Wu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Jian H; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Chen Y; Department of Oncology, Jilin Cancer Hospital, Changchun, China.
  • Wang Q; Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China.
  • Fang J; Department of Thoracic Medical Oncology, Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, China.
  • Wang Z; Department of Thoracic Medical Oncology, Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, China.
  • Hu Y; Department of Thoracic Medical Oncology, Hubei Cancer Hospital, Wuhan, China.
  • Sun M; Department of Oncology, Jinan Central Hospital affiliated to Shandong University, Jinan, China.
  • Han L; Department of Oncology, Xuzhou Central Hospital, Xuzhou, China.
  • Miao L; Department of Respiratory Medicine, Nanjing University Mdical School affiliated to Nanjing Drum Tower Hospital, Nanjing, China.
  • Ding C; Department of Respiratory Medicine, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
  • Cui J; Department of Oncology, Jilin University First Hospital, Changchun, China.
  • Li B; Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Pan Y; Department of Oncology, Anhui Provincial Hospital, Hefei, China.
  • Li X; Department of Oncology, Zhengzhou University First Affiliated Hospital, Zhengzhou, China.
  • Ye F; Department of Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Liu A; Department of Oncology, Nanchang University Second Affiliated Hospital, Nanchang, China.
  • Wang K; Department of Respiratory Medicine, Sichuan University West China Hospital, Chengdu, China.
  • Cang S; Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, China.
  • Zhou H; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.
  • Sun X; Department of Biostatistics and Information, Innovent Biologics, Suzhou, China.
  • Ferry D; Department of Oncology Medical Strategy, Eli Lilly and Company, New York, NY, USA.
  • Lin Y; Eli Lilly and Company, Indianapolis, IN, USA.
  • Wang S; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.
  • Zhang W; Department of Biostatistics and Information, Innovent Biologics, Suzhou, China.
  • Zhang C; Department of Medical Science and Strategy Oncology, Innovent Biologics, Suzhou, China.
Lancet Oncol ; 23(9): 1167-1179, 2022 09.
Article en En | MEDLINE | ID: mdl-35908558
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Biosimilares Farmacéuticos / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Biosimilares Farmacéuticos / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article